Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sanofi has committed up to $1.9 billion to acquire Dren Bio's bispecific antibody for autoimmune disease, adding to its investments in the immunology portfolio. The deal comes after the tragic death of a patient who had taken the gene therapy Elevydys, prompting the Duchenne patient community to vow to push on. Paratek Pharmaceuticals has acquired Optinose for up to $330 million, while Senate Democrats demand the return of fired CDC staff. Sino Biological has developed recombinant antigens for the 2025-2026 influenza vaccine strains, and Purdue has filed for bankruptcy to support a $7.4 billion opioid settlement. Doctors continue to rally behind vaccines amidst doubts and misinformation, and Novartis' intrathecal Zolgensma has shown effectiveness in older children. TC Biopharm and Cargo have enacted steep workforce reductions. Pharmaceutical companies are also preparing for upcoming events, including webinars on AI regulation and drug development. Job opportunities in the pharmaceutical industry are available at companies like Takeda, Eli Lilly and Company, and Novo Nordisk.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has made a $1 billion investment in Oxford Biotherapeutics to gain access to their antibody-drug conjugate platform for cancer targets. Cargo has laid off 90% of its staff and is exploring potential business combinations. Trump is considering budget cuts to the CDC's HIV prevention program, which could impact HIV drugmakers like Gilead and Merck. The rise of GLP-1 weight loss drugs is compared to the early days of PD-1 inhibitors, with differences in the market suggesting history may not repeat itself. Sino Biological has developed recombinant antigens for the 2025-2026 influenza vaccine strains. Servier has acquired a solid tumor asset in a deal with Black Diamond.The text discusses the similarities between the rise of GLP-1 weight loss drugs and PD-1 inhibitors in the pharmaceutical industry. It also explores the impact of ongoing conflicts on drug development, highlights a new company, Mirador, focusing on inflammatory and fibrotic diseases, and looks at drugs facing patent cliffs. Additionally, it mentions Wacker Biotech as a partner for advanced therapies and provides updates on various pharmaceutical companies.Thank you for tuning in to Pharma and Biotech daily. Stay informed with us for more updates on the latest news in the industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Sarepta's DMD gene therapy patient dies, causing a 22% drop in shares.Sarepta experienced a significant setback as a patient participating in their DMD gene therapy trial tragically passed away, leading to a 22% decrease in their shares.## Arbor raises $73.5 million for gene editing research.Arbor successfully secured $73.5 million in funding to further their research in gene editing, showcasing the growing interest and investment in this innovative field.## Opko and Entera collaborate on oral GLP-1/glucagon drug development.Opko and Entera have joined forces to collaborate on the development of an oral GLP-1/glucagon drug, combining their expertise to potentially revolutionize treatment options for patients.## Mirador aims to be a leading I&I breakthrough by 2030.Mirador has set ambitious goals to become a leading breakthrough in the field of inflammation and immunology by the year 2030, highlighting their commitment to advancing healthcare solutions.## Sino Biological offers reagents for 2025-2026 influenza vaccine strains.Sino Biological is providing reagents for the upcoming 2025-2026 influenza vaccine strains, contributing to the global efforts to combat infectious diseases and protect public health.## AstraZeneca invests $1.35 billion in subcutaneous cancer drugs with Alteogen alliance.AstraZeneca has made a substantial investment of $1.35 billion in subcutaneous cancer drugs through a strategic alliance with Alteogen, signaling their dedication to advancing oncology treatments.## DYNE's Duchenne exon skipping oligomer shows promising clinical effect.DYNE's Duchenne exon skipping oligomer has demonstrated promising clinical effects, offering hope for patients with this debilitating genetic disorder and potentially paving the way for new treatment options.Thank you for tuning in to Pharma and Biotech daily, where we bring you the latest updates and developments shaping the pharmaceutical and biotechnology industries. Stay informed and stay ahead in the world of healthcare innovation.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AstraZeneca has recently made a significant investment of up to $1 billion in cell therapy through the acquisition of esobiotec. This move is part of AstraZeneca's larger strategy to expand in the cell therapy space, positioning itself to be a major player in the market. Dyne is also looking to file for accelerated approval for its Duchenne exon skipping oligomer, while Taiho Pharmaceutical has acquired ADC partner Araris for up to $1.1 billion. Alnylam is expected to enter the transthyretin amyloid cardiomyopathy market, which is projected to reach $11.2 billion by 2030.Sino Biological has developed reagents for the 2025-2026 influenza vaccine strains, offering a range of recombinant proteins for vaccine development. The pharmaceutical industry is seeing significant activity in various therapy areas, with companies making strategic investments and advancements in research and development.Alnylam is awaiting approval for their drug Amvuttra in the transthyretin amyloid cardiomyopathy market, which is currently dominated by Pfizer and BridgeBio. The obesity drug market is becoming increasingly competitive, with companies focusing on overall health benefits rather than just weight loss. Biopharma companies are now exploring the use of CAR T cell therapies for autoimmune disorders, with several readouts expected this year. Ionis and Ultragenyx are competing to develop treatments for Angelman syndrome, while Neuren is trying to catch up.Overall health outcomes are becoming more important in the obesity drug market, with successful studies in therapeutic areas like cardiovascular and sleep apnea providing a market advantage. Other news includes flu vaccine recommendations from the FDA and updates on drugs for alcohol use disorder, plaque psoriasis, breast cancer, and weight loss. The biopharma industry continues to evolve, with readers encouraged to provide suggestions for future coverage topics.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Altimmune, a biopharmaceutical company based in Maryland, has announced plans to test an investigational drug based on GLP-1 for the treatment of alcohol use disorder. This drug is also being studied by Eli Lilly and Novo Nordisk for alcohol- and liver-related conditions. Altimmune joins these companies in exploring the potential of GLP-1 agonists for this indication. The recommendations for flu vaccine usage were recently made by the FDA in a closed session involving representatives from CBER, the CDC, and the Department of Defense.In other news, Pfizer has ended a trial for an early-stage cancer drug, Sutro has cut half of its staff and deprioritized a drug for ovarian cancer, and Pliant has implemented a poison pill strategy. Additionally, Wacker Biotech is offering services for advanced therapies, including process development and production of DNA and RNA. The biotech industry continues to see shifts and developments in various companies and research areas.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The Trump administration has withdrawn CDC nominee Dave Weldon at the last minute, while NIH and FDA picks advance. Acelyrin has implemented a poison pill strategy to prevent Tang Capital from acquiring the company. Johnson & Johnson and Legend Biotech are investing $150 million to increase Carvykti production. Mallinckrodt and Endo have announced a $6.7 billion merger. Wacker Biotech offers services for advanced therapies. Other news includes updates on Amgen's Uplizna, J&J's talc lawsuit, and Roche's obesity play.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Bluebird bio has made the decision to go private in order to restructure and focus on long-term growth amidst declining valuations and funding challenges in the biotech industry. This move reflects a strategic shift in response to the current market conditions. Johnson & Johnson continues to face legal battles over talc products, with a pending ruling that could potentially resolve the issue. This ongoing litigation highlights the importance of product safety and regulatory compliance in the pharmaceutical industry. In other news, Viking has secured a supply of an obesity pill candidate, demonstrating a commitment to addressing unmet medical needs in the field of obesity treatment. Roche has also made a significant play in the obesity market with a potential $5.3 billion pact, signaling confidence in the potential of this therapeutic area. The COVID-19 pandemic has had lasting impacts on the life sciences sector, prompting companies to adapt and innovate in response to changing market dynamics. The industry continues to evolve in light of these challenges, driving progress and innovation in healthcare. Overall, these developments underscore the dynamic nature of the pharmaceutical and biotech industries, highlighting the importance of strategic decision-making and adaptability in a rapidly changing landscape.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Bristol Myers Squibb (BMS) has acquired 2seventy, the partner of Abecma, for $286 million, ending their cost-sharing agreement. Abecma generated $406 million in 2024, with BMS paying $43 million to 2seventy as part of their profit-sharing agreement.Beam Therapeutics has achieved genetic correction in AATD, while Viking secured a 1 billion supply of an obesity pill candidate. Novavax, Roche, and other companies are also making significant moves in the industry.The editorial reflects on the five years of COVID-19 and its ongoing impacts on the life sciences industry. Stay tuned for more updates on these developments and more in the world of Pharma and Biotech.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo's next-generation weight loss drug, cagrisema, has disappointed once again with lower-than-expected weight loss results. The latest data showed only a 15.7% weight loss in patients with diabetes after 68 weeks, below the company's projections. This news has caused Novo's stock to dip. Additionally, side effects associated with GLP-1-based obesity drugs are turning patients away from this type of treatment. Despite efforts to mitigate these side effects, studies show that various factors are causing patients to discontinue treatment.In other news, Johnson & Johnson's oral IL-23R blocker has set a new standard in plaque psoriasis treatment, outperforming Bristol Myers Squibb's Sotyktu. BMS's Sotyktu did, however, notch a phase III win in psoriatic arthritis. Novo is also conducting studies on GLP-1s for addiction, limited to ongoing phase II trials. Overall, the landscape of weight loss and skin condition treatments is evolving, with new drugs showing promise and competition heating up in the market.Drugmakers are focusing on reducing the side effects of GLP-1-based obesity drugs to address high discontinuation rates among patients. Novavax is applying lessons learned from the COVID-19 pandemic as it looks towards developing other novel vaccines. The FDA faces a challenging decision on biomarker-based label restrictions for certain cancer drugs, while J&J has axed a late-stage depression trial due to underwhelming efficacy.Other news includes AstraZeneca's positive data on Imfinzi for stomach cancer and Takeda's drug reducing the need for blood withdrawals in clinical trials. Novavax is also working with pharma partners to bring new vaccines to market. The FDA is dealing with staff and site turnover, and more job opportunities in the biopharma industry are available.Readers are encouraged to provide feedback on what topics they would like to see covered in future articles.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. J&J has recently halted a late-stage depression trial due to lack of efficacy. Analysts do not believe this will have a significant impact on the company's broader neuroscience strategy. Meanwhile, there seems to be confusion at the FDA with terminations and reversals happening. In other news, Novo Nordisk has conducted limited studies on GLP-1s for addiction. Biogen and Eisai are facing setbacks with Leqembi overseas. There are potential FDA changes under commissioner Marty Makary. The FDA's priority review vouchers are in need of transparency. AstraZeneca has presented strong data for Imfinzi in stomach cancer. Atea Pharmaceuticals has made the decision to cut its workforce. Novo Nordisk is entering a legal battle against GLP-1 compounders, while Lilly has achieved a victory in a different matter. Pharmaceutical executives have recently shared insights on trust, technology, and the future at the WEF. Overall, there are various developments happening in the Pharma and Biotech industry that are worth keeping an eye on.